Doron Levy: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
Next edit →
Content deleted Content added
VisualWikitext
←Created page with '{{Infobox academic | name = Doron Levy | image = | birth_date = | birth_place = | nationality = | occupation = Mathematician, scientist, magician, and academic | title = | awards = | website = | education = B.Sc. in Mathematics and Physics<br>M.Sc. in Applied Mathematics<br>Ph.D. in Applied Mathematics | alma_mater = Tel Av...'
 
Filled in 34 bare reference(s) with reFill 2
Line 18: Line 18:
| workplaces = [[École normale supérieure (Paris)]]<br>[[Sorbonne University|Paris 6 University (Sorbonne University)]]<br>[[University of California, Berkeley]]<br>[[Lawrence Berkeley National Laboratory]]<br>[[Stanford University]]<br>[[University of Maryland, College Park]]
| workplaces = [[École normale supérieure (Paris)]]<br>[[Sorbonne University|Paris 6 University (Sorbonne University)]]<br>[[University of California, Berkeley]]<br>[[Lawrence Berkeley National Laboratory]]<br>[[Stanford University]]<br>[[University of Maryland, College Park]]
}}
}}
'''Doron Levy''' is a [[mathematician]], [[scientist]], [[magic (illusion)|magician]], and academic. He is a Professor and Chair at the Department of Mathematics at the [[University of Maryland, College Park]].<ref name=aaa>{{cite web|url=https://www.journals.elsevier.com/immunoinformatics/editorial-board/dr-doron-levy-phd|title=Dr. Doron Levy}}</ref> He is also the Director of the Brin Mathematics Research Center.<ref name =ooo>{{cite web|url=https://brinmrc.umd.edu/people/director.html|title=Director}}</ref>
'''Doron Levy''' is a [[mathematician]], [[scientist]], [[magic (illusion)|magician]], and academic. He is a Professor and Chair at the Department of Mathematics at the [[University of Maryland, College Park]].<ref name="aaa">{{Cite web|url=https://www.journals.elsevier.com/immunoinformatics/editorial-board/journals.elsevier.com/immunoinformatics/editorial-board/dr-doron-levy-phd|title=Dr. Doron Levy, PhD - Editorial Board - ImmunoInformatics - Journal - Elsevier|website=www.journals.elsevier.com}}</ref> He is also the Director of the Brin Mathematics Research Center.<ref name =ooo>{{Cite web|url=http://www.brinmrc.umd.edu/people/director.html|title=MRC Director|website=Brin MRC}}</ref>


Levy's research encompasses the field of [[numerical analysis]], applied nonlinear PDEs, and [[biology]] and medical applications, particularly focusing on analyzing cancer dynamics, [[immunology]], and [[Cell (biology)|cell]] [[motility]]. He has written more than 100 peer-reviewed articles. He is the recipient of the [[National Science Foundation CAREER Award|National Science Foundation Career Award]].<ref name=nsf>{{cite web|url=https://www.nsf.gov/awardsearch/showAward?AWD_ID=0820817|title=NSF Award Search: Award # 0820817 - CAREER: Partial Differential Equation-based Image Processing with Applications to Radiation Oncology}}</ref>
Levy's research encompasses the field of [[numerical analysis]], applied nonlinear PDEs, and [[biology]] and medical applications, particularly focusing on analyzing cancer dynamics, [[immunology]], and [[Cell (biology)|cell]] [[motility]]. He has written more than 100 peer-reviewed articles. He is the recipient of the [[National Science Foundation CAREER Award|National Science Foundation Career Award]].<ref name=nsf>{{Cite web|url=https://www.nsf.gov/awardsearch/showAward?AWD_ID=0820817|title=NSF Award Search: Award # 0820817 - CAREER: Partial Differential Equation-based Image Processing with Applications to Radiation Oncology|website=www.nsf.gov}}</ref>


Levy is a Fellow of the [[John Simon Guggenheim Memorial Foundation]]<ref name=gf>{{cite web|url=https://www.gf.org/fellows/doron-levy/|title=Doron Levy - John Simon Guggenheim Memorial Foundation}}</ref> He is the Editor-in-Chief of ''ImmunoInformatics''.<ref name=aaa/>
Levy is a Fellow of the [[John Simon Guggenheim Memorial Foundation]]<ref name=gf>{{Cite web|url=https://www.gf.org/fellows/doron-levy/|title=Doron Levy|website=John Simon Guggenheim Memorial Foundation...}}</ref> He is the Editor-in-Chief of ''ImmunoInformatics''.<ref name=aaa/>


==Education==
==Education==
Levy earned his Baccalaureate degree in [[Mathematics]] and [[Physics]] in 1991 and completed a Masters in [[Applied Mathematics]] in 1994 from [[Tel Aviv University]]. His Master's thesis was titled "From Semi-Discrete to Fully-Discrete: The Stability of Runge-Kutta Schemes by the Energy Method".<ref>{{cite web|url=https://epubs.siam.org/doi/abs/10.1137/S0036144597316255|title=From Semidiscrete to Fully Discrete: Stability of Runge--Kutta Schemes by The Energy Method - SIAM Review}}</ref> In 1997, he received a Ph.D. in Applied Mathematics under the guidance of [[Eitan Tadmor]], with a thesis on "Topics in Approximate Methods for Non-Linear Partial Differential Equations." Afterward, he held several post-doctorate fellowships at [[Pierre and Marie Curie University|Laboratoire d'Analyse Numerique (University of Paris 6)]], [[École normale supérieure (Paris)]], [[University of California, Berkeley]], and the [[Lawrence Berkeley National Laboratory]].<ref name=bbb>{{cite web|url=https://www.journals.elsevier.com/immunoinformatics/editorial-board/dr-doron-levy-phd|title=Dr. Doron Levy, PhD - Editorial Board - ImmunoInformatics - Journal - Elsevier}}</ref>
Levy earned his Baccalaureate degree in [[Mathematics]] and [[Physics]] in 1991 and completed a Masters in [[Applied Mathematics]] in 1994 from [[Tel Aviv University]]. His Master's thesis was titled "From Semi-Discrete to Fully-Discrete: The Stability of Runge-Kutta Schemes by the Energy Method".<ref>{{Cite journal|url=http://epubs.siam.org/doi/10.1137/S0036144597316255|title=From Semidiscrete to Fully Discrete: Stability of Runge--Kutta Schemes by The Energy Method|first1=Doron|last1=Levy|first2=Eitan|last2=Tadmor|date=January 11, 1998|journal=SIAM Review|volume=40|issue=1|pages=40–73|via=CrossRef|doi=10.1137/S0036144597316255}}</ref> In 1997, he received a Ph.D. in Applied Mathematics under the guidance of [[Eitan Tadmor]], with a thesis on "Topics in Approximate Methods for Non-Linear Partial Differential Equations." Afterward, he held several post-doctorate fellowships at [[Pierre and Marie Curie University|Laboratoire d'Analyse Numerique (University of Paris 6)]], [[École normale supérieure (Paris)]], [[University of California, Berkeley]], and the [[Lawrence Berkeley National Laboratory]].<ref name="aaa"/>


==Career==
==Career==
Following his post-doctoral fellowship at Berkeley in 2000, Levy joined the Department of Mathematics at [[Stanford University]] as an Assistant Professor. In 2007, he was appointed as Associate Professor of Mathematics and a member of the [[Center for Scientific Computation and Mathematical Modeling]] (CSCAMM) at the University of Maryland, College Park. In 2014, he became a Pauli Fellow at the Wolfgang Pauli Institute of the [[University of Vienna]] in [[Austria]].<ref>{{cite web|url=https://www.wpi.ac.at/theme_view.php?id_theme=125|title=athematical models in Biology and Medicine (2017/2018)}}</ref> Since 2011, he has been a Professor at the Department of Mathematics & Center for Scientific Computation and Mathematical Modeling of the University of Maryland, College Park.<ref>{{cite web|url=https://www-math.umd.edu/people/faculty/item/385-dlevy.html |title=Department of Mathematics - Levy, Doron }}</ref>
Following his post-doctoral fellowship at Berkeley in 2000, Levy joined the Department of Mathematics at [[Stanford University]] as an Assistant Professor. In 2007, he was appointed as Associate Professor of Mathematics and a member of the [[Center for Scientific Computation and Mathematical Modeling]] (CSCAMM) at the University of Maryland, College Park. In 2014, he became a Pauli Fellow at the Wolfgang Pauli Institute of the [[University of Vienna]] in [[Austria]].<ref>{{Cite web|url=https://www.wpi.ac.at/theme_view.php?id_theme=125|title=Wolfgang Pauli Institute (WPI)|website=www.wpi.ac.at}}</ref> Since 2011, he has been a Professor at the Department of Mathematics & Center for Scientific Computation and Mathematical Modeling of the University of Maryland, College Park.<ref>{{Cite web|url=https://www-math.umd.edu/people/faculty/item/385-dlevy.html|title=Department of Mathematics - Levy, Doron|website=www-math.umd.edu}}</ref>


As of 2020, Levy has been a Chair at the Department of Mathematics & the Director of the Center for Scientific Computation and Mathematical Modeling (CSCAMM) of the University of Maryland, College Park.<ref name=aaa/>
As of 2020, Levy has been a Chair at the Department of Mathematics & the Director of the Center for Scientific Computation and Mathematical Modeling (CSCAMM) of the University of Maryland, College Park.<ref name=aaa/>
Line 36: Line 36:


===Numerical analysis===
===Numerical analysis===
During his early research career, Levy worked on developing and analyzing high-order numerical methods for approximating solutions to hyperbolic conservation law and related equations. He developed novel methods for approximating solutions to nonlinear partial differential equations including Euler equations, Navier-Stokes equations, Hamilton-Jacobi equations, nonlinear dispersive equations. Some of the approximation methods he developed used Weighted Essentially Non-Oscillatory (WENO) schemes.<ref>{{cite web|url=https://www.sciencedirect.com/science/article/abs/pii/S0168927499001075|title=On the behavior of the total variation in CWENO methods for conservation laws}}</ref> He developed a third-order central scheme for approximating solutions of multidimensional hyperbolic conservation laws<ref>{{cite web|url=https://epubs.siam.org/doi/abs/10.1137/S1064827599359461|title=Compact Central WENO Schemes for Multidimensional Conservation Laws}}</ref> and 2D conservation laws using compact central WENO reconstructions.<ref>{{cite web|url=https://www.sciencedirect.com/science/article/abs/pii/S0168927499001087|title=A third order central WENO scheme for 2D conservation laws }}</ref> In a series of works with Steve Bryson, he proposed new high-order central schemes<ref>{{cite web|url=https://link.springer.com/chapter/10.1007/978-88-470-2089-4_4|title=High-order central WENO schemes for 1D Hamilton-Jacobi equations }}</ref> for approximating solutions of multidimensional Hamilton-Jacobi equations.<ref>{{cite web|url=https://epubs.siam.org/doi/abs/10.1137/S0036142902408404|title=High-Order Central WENO Schemes for Multidimensional Hamilton-Jacobi Equations}}</ref><ref>{{cite web|url=https://epubs.siam.org/doi/abs/10.1137/040612002|title=Central WENO Schemes for Hamilton–Jacobi Equations on Triangular Meshes}}</ref>
During his early research career, Levy worked on developing and analyzing high-order numerical methods for approximating solutions to hyperbolic conservation law and related equations. He developed novel methods for approximating solutions to nonlinear partial differential equations including Euler equations, Navier-Stokes equations, Hamilton-Jacobi equations, nonlinear dispersive equations. Some of the approximation methods he developed used Weighted Essentially Non-Oscillatory (WENO) schemes.<ref>{{Cite journal|url=https://www.sciencedirect.com/science/article/pii/S0168927499001075|title=On the behavior of the total variation in CWENO methods for conservation laws|first1=Doron|last1=Levy|first2=Gabriella|last2=Puppo|first3=Giovanni|last3=Russo|date=May 1, 2000|journal=Applied Numerical Mathematics|volume=33|issue=1|pages=407–414|via=ScienceDirect|doi=10.1016/S0168-9274(99)00107-5}}</ref> He developed a third-order central scheme for approximating solutions of multidimensional hyperbolic conservation laws<ref>{{Cite journal|url=http://epubs.siam.org/doi/10.1137/S1064827599359461|title=Compact Central WENO Schemes for Multidimensional Conservation Laws|first1=Doron|last1=Levy|first2=Gabriella|last2=Puppo|first3=Giovanni|last3=Russo|date=January 11, 2000|journal=SIAM Journal on Scientific Computing|volume=22|issue=2|pages=656–672|via=CrossRef|doi=10.1137/S1064827599359461}}</ref> and 2D conservation laws using compact central WENO reconstructions.<ref>{{Cite journal|url=https://www.sciencedirect.com/science/article/pii/S0168927499001087|title=A third order central WENO scheme for 2D conservation laws|first1=Doron|last1=Levy|first2=Gabriella|last2=Puppo|first3=Giovanni|last3=Russo|date=May 1, 2000|journal=Applied Numerical Mathematics|volume=33|issue=1|pages=415–421|via=ScienceDirect|doi=10.1016/S0168-9274(99)00108-7}}</ref> In a series of works with Steve Bryson, he proposed new high-order central schemes<ref>{{Cite web|url=https://link.springer.com/chapter/10.1007/978-88-470-2089-4_4|title=High-order central WENO schemes for 1D Hamilton-Jacobi equations|first1=S.|last1=Bryson|first2=D.|last2=Levy|editor-first1=Franco|editor-last1=Brezzi|editor-first2=Annalisa|editor-last2=Buffa|editor-first3=Stefania|editor-last3=Corsaro|editor-first4=Almerico|editor-last4=Murli|date=August 11, 2003|publisher=Springer Milan|pages=45–54|via=Springer Link|doi=10.1007/978-88-470-2089-4_4}}</ref> for approximating solutions of multidimensional Hamilton-Jacobi equations.<ref>{{Cite journal|url=http://epubs.siam.org/doi/10.1137/S0036142902408404|title=High-Order Central WENO Schemes for Multidimensional Hamilton-Jacobi Equations|first1=Steve|last1=Bryson|first2=Doron|last2=Levy|date=January 11, 2003|journal=SIAM Journal on Numerical Analysis|volume=41|issue=4|pages=1339–1369|via=CrossRef|doi=10.1137/S0036142902408404}}</ref><ref>{{Cite journal|url=http://epubs.siam.org/doi/10.1137/040612002|title=Central WENO Schemes for Hamilton–Jacobi Equations on Triangular Meshes|first1=Doron|last1=Levy|first2=Suhas|last2=Nayak|first3=Chi‐Wang|last3=Shu|first4=Yong‐Tao|last4=Zhang|date=January 11, 2006|journal=SIAM Journal on Scientific Computing|volume=28|issue=6|pages=2229–2247|via=CrossRef|doi=10.1137/040612002}}</ref>


===Cancer dynamics and the immune system===
===Cancer dynamics and the immune system===
Levy contributed to cancer dynamics by formulating a set of computational and mathematical tools designed for specific types of cancer.<ref>{{cite web|url=https://www.cambridge.org/core/journals/mathematical-modelling-of-natural-phenomena/article/abs/new-computational-tools-for-modeling-chronic-myelogenous-leukemia/290986D74A109C699A4BFDC626D829AD|title=New Computational Tools for Modeling Chronic Myelogenous Leukemia}}</ref> He discussed the need for mathematical models to understand the complexity of breast and ovarian cancers<ref>{{cite web|url=https://wires.onlinelibrary.wiley.com/doi/abs/10.1002/wsbm.1343|title=Mathematical models of breast and ovarian cancers}}</ref> and proposed a model to explain the failure of transvaginal ultrasound-based screening in detecting low-volume high-grade serous ovarian cancer.<ref>{{cite web|url=https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0156661|title=Modeling the Dynamics of High-Grade Serous Ovarian Cancer Progression for Transvaginal Ultrasound-Based Screening and Early Detection}}</ref> In a collaborative study, he investigated the effects of regulatory T cell switching the immune response and identified a biologically testable range for the switching parameter.<ref>{{cite web|url=https://link.springer.com/article/10.1007/s11538-013-9875-9|title=Functional Switching and Stability of Regulatory T Cells }}</ref> Furthermore, he presented mathematical models for studying cancer cell growth dynamics<ref>{{cite web|url=https://www.sciencedirect.com/science/article/abs/pii/S0022519314006699|title=Modeling intrinsic heterogeneity and growth of cancer cells}}</ref> in response to antimitotic drug treatment in vitro,<ref>{{cite web|url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2017.00189/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Oncology&id=276810|title=Modeling Cancer Cell Growth Dynamics In vitro in Response to Antimitotic Drug Treatment}}</ref> to understand the immunogenic effects of LSD1 inhibition on tumor growth and T cell dynamics,<ref>{{cite web|url=https://link.springer.com/article/10.1007/s11538-020-00842-8|title=Modeling LSD1-Mediated Tumor Stagnation}}</ref> and for the interaction between immune response and cancer cells in chronic myelogenous leukemia and analyzes the stability of steady states.<ref>{{cite web|url=https://link.springer.com/article/10.1007/s11538-017-0272-7|title=Stability Analysis of a Model of Interaction Between the Immune System and Cancer Cells in Chronic Myelogenous Leukemia}}</ref>
Levy contributed to cancer dynamics by formulating a set of computational and mathematical tools designed for specific types of cancer.<ref>{{Cite journal|url=https://www.cambridge.org/core/journals/mathematical-modelling-of-natural-phenomena/article/abs/new-computational-tools-for-modeling-chronic-myelogenous-leukemia/290986D74A109C699A4BFDC626D829AD|title=New Computational Tools for Modeling Chronic Myelogenous Leukemia|first1=M. M.|last1=Peet|first2=P. S.|last2=Kim|first3=S.-I.|last3=Niculescu|first4=D.|last4=Levy|date=January 11, 2009|journal=Mathematical Modelling of Natural Phenomena|volume=4|issue=2|pages=119–139|via=Cambridge University Press|doi=10.1051/mmnp/20094206}}</ref> He discussed the need for mathematical models to understand the complexity of breast and ovarian cancers<ref>{{Cite journal|url=https://onlinelibrary.wiley.com/doi/10.1002/wsbm.1343|title=Mathematical models of breast and ovarian cancers|first1=Dana‐Adriana|last1=Botesteanu|first2=Stanley|last2=Lipkowitz|first3=Jung‐Min|last3=Lee|first4=Doron|last4=Levy|date=July 11, 2016|journal=WIREs Systems Biology and Medicine|volume=8|issue=4|pages=337–362|via=CrossRef|doi=10.1002/wsbm.1343|pmid=27259061|pmc=PMC4911289}}</ref> and proposed a model to explain the failure of transvaginal ultrasound-based screening in detecting low-volume high-grade serous ovarian cancer.<ref>{{Cite journal|url=https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0156661|title=Modeling the Dynamics of High-Grade Serous Ovarian Cancer Progression for Transvaginal Ultrasound-Based Screening and Early Detection|first1=Dana-Adriana|last1=Botesteanu|first2=Jung-Min|last2=Lee|first3=Doron|last3=Levy|date=June 3, 2016|journal=PLOS ONE|volume=11|issue=6|pages=e0156661|via=PLoS Journals|doi=10.1371/journal.pone.0156661|pmid=27257824|pmc=PMC4892570}}</ref> In a collaborative study, he investigated the effects of regulatory T cell switching the immune response and identified a biologically testable range for the switching parameter.<ref>{{Cite journal|url=https://doi.org/10.1007/s11538-013-9875-9|title=Functional Switching and Stability of Regulatory T Cells|first1=Shelby|last1=Wilson|first2=Doron|last2=Levy|date=October 1, 2013|journal=Bulletin of Mathematical Biology|volume=75|issue=10|pages=1891–1911|via=Springer Link|doi=10.1007/s11538-013-9875-9}}</ref> Furthermore, he presented mathematical models for studying cancer cell growth dynamics<ref>{{Cite journal|url=https://www.sciencedirect.com/science/article/pii/S0022519314006699|title=Modeling intrinsic heterogeneity and growth of cancer cells|first1=James M.|last1=Greene|first2=Doron|last2=Levy|first3=King Leung|last3=Fung|first4=Paloma S.|last4=Souza|first5=Michael M.|last5=Gottesman|first6=Orit|last6=Lavi|date=February 21, 2015|journal=Journal of Theoretical Biology|volume=367|pages=262–277|via=ScienceDirect|doi=10.1016/j.jtbi.2014.11.017}}</ref> in response to antimitotic drug treatment in vitro,<ref>{{Cite journal|url=https://www.frontiersin.org/articles/10.3389/fonc.2017.00189|title=Modeling Cancer Cell Growth Dynamics In vitro in Response to Antimitotic Drug Treatment|first1=Alexander|last1=Lorz|first2=Dana-Adriana|last2=Botesteanu|first3=Doron|last3=Levy|date=August 11, 2017|journal=Frontiers in Oncology|volume=7|via=Frontiers|doi=10.3389/fonc.2017.00189/full?&utm_source=email_to_authors_&utm_medium=email&utm_content=t1_11.5e1_author&utm_campaign=email_publication&field=&journalname=frontiers_in_oncology&id=276810}}</ref> to understand the immunogenic effects of LSD1 inhibition on tumor growth and T cell dynamics,<ref>{{Cite journal|url=https://doi.org/10.1007/s11538-020-00842-8|title=Modeling LSD1-Mediated Tumor Stagnation|first1=Jesse|last1=Milzman|first2=Wanqiang|last2=Sheng|first3=Doron|last3=Levy|date=January 12, 2021|journal=Bulletin of Mathematical Biology|volume=83|issue=2|pages=15|via=Springer Link|doi=10.1007/s11538-020-00842-8}}</ref> and for the interaction between immune response and cancer cells in chronic myelogenous leukemia and analyzes the stability of steady states.<ref>{{Cite journal|url=https://doi.org/10.1007/s11538-017-0272-7|title=Stability Analysis of a Model of Interaction Between the Immune System and Cancer Cells in Chronic Myelogenous Leukemia|first1=Apollos|last1=Besse|first2=Geoffrey D.|last2=Clapp|first3=Samuel|last3=Bernard|first4=Franck E.|last4=Nicolini|first5=Doron|last5=Levy|first6=Thomas|last6=Lepoutre|date=May 1, 2018|journal=Bulletin of Mathematical Biology|volume=80|issue=5|pages=1084–1110|via=Springer Link|doi=10.1007/s11538-017-0272-7}}</ref>


Levy analyzed cancer's immune response mechanisms, particularly in chronic myeloid leukemia, providing insights into the role of the immune response and drug therapy in controlling the disease.<ref>{{cite web|url=https://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=1177&context=bamm|title=The role of the autologous immune response in chronic myelogenous leukemia}}</ref> He also demonstrated that the autologous immune system may play a role in the BCR-ABL transcript variations observed in chronic phase chronic myelogenous leukemia patients on imatinib therapy.<ref>{{cite web|url=https://www.tandfonline.com/doi/full/10.1080/2162402X.2015.1122159|title=Full article: BCR-ABL transcript variations in chronic phase chronic myelogenous leukemia patients on imatinib first-line: Possible role of the autologous immune system}}</ref> Considering the problem of drug resistance in cancer<ref>{{cite web|url=https://www.sciencedirect.com/science/article/abs/pii/S1368764612000040|title=The dynamics of drug resistance: A mathematical perspective}}</ref> he suggested a simple compartmental system of ordinary differential equations to model it<ref>{{cite web|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877932/|title=An elementary approach to modeling drug resistance in cancer}}</ref> and stated that drug resistance depends on the turnover rate of cancer cells.<ref>{{cite web|url=https://link.springer.com/chapter/10.1007/978-3-642-14998-6_141|title=Drug Resistance always Depends on the Turnover Rate}}</ref> Additionally, he extended a model of drug resistance in solid tumors to explore the dynamics of resistance levels and the emergence of heterogeneous tumors in response to chemotherapy.<ref>{{cite web|url=https://link.springer.com/article/10.1007/s11538-017-0359-1|title= Modeling the Dynamics of Heterogeneity of Solid Tumors in Response to Chemotherapy}}</ref><ref>{{cite web|url=https://link.springer.com/article/10.1007/s11538-017-0334-x|title=Modeling the Transfer of Drug Resistance in Solid Tumors}}</ref> Conducting a study on cervical cancer, he investigated the efficacy of combination immunotherapy using engineered T cells and IL-2.<ref>{{cite web|url=https://www.sciencedirect.com/science/article/abs/pii/S0022519320302587|title=Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer - ScienceDirect}}</ref> Moreover, he assessed the influence of cell density,<ref>{{cite web|url=https://aacrjournals.org/cancerres/article/76/10/2882/609063/Mathematical-Modeling-Reveals-That-Changes-to|title=Mathematical Modeling Reveals That Changes to Local Cell Density Dynamically Modulate Baseline Variations in Cell Growth and Drug Response}}</ref> intratumoral heterogeneity,<ref>{{cite web|url=https://aacrjournals.org/cancerres/article/73/24/7168/586395/The-Role-of-Cell-Density-and-Intratumoral|title=The Role of Cell Density and Intratumoral Heterogeneity in Multidrug Resistance}}</ref> and mutations in multidrug resistance,<ref>{{cite web|url=https://link.springer.com/article/10.1007/s11538-014-9936-8|title=The Impact of Cell Density and Mutations in a Model of Multidrug Resistance in Solid Tumors}}</ref> considering the continuum model as the most suitable approach for modeling resistance heterogeneity in metastasis.<ref>{{cite web|url=https://www.cell.com/trends/molecular-medicine/fulltext/S1471-4914(13)00225-6|title=Simplifying the complexity of resistance heterogeneity in metastasis: Trends in Molecular Medicine}}</ref><ref>{{cite web|url=https://www.sciencedirect.com/science/article/pii/S0307904X1830341X?via%3Dihub|title=Modeling continuous levels of resistance to multidrug therapy in cancer}}</ref> In collaboration with Heyrim Cho, he also investigated the impact of competition between cancer cells and healthy cells on optimal drug delivery and indicated that in scenarios with moderate competition, combination therapies are more effective, whereas in highly competitive situations, targeted drugs prove to be more effective.<ref>{{cite web|url=https://www.mmnp-journal.org/articles/mmnp/abs/2020/01/mmnp180193/mmnp180193.html|title=The impact of competition between cancer cells and healthy cells on optimal drug delivery}}</ref>
Levy analyzed cancer's immune response mechanisms, particularly in chronic myeloid leukemia, providing insights into the role of the immune response and drug therapy in controlling the disease.<ref>{{Cite web|url=https://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=1177&context=bamm|title=The role of the autologous immune response in chronic myelogenous leukemia}}</ref> He also demonstrated that the autologous immune system may play a role in the BCR-ABL transcript variations observed in chronic phase chronic myelogenous leukemia patients on imatinib therapy.<ref>{{Cite journal|url=https://www.tandfonline.com/doi/full/10.1080/2162402X.2015.1122159|title=BCR-ABL transcript variations in chronic phase chronic myelogenous leukemia patients on imatinib first-line: Possible role of the autologous immune system|first1=Geoffrey D.|last1=Clapp|first2=Thomas|last2=Lepoutre|first3=Franck E.|last3=Nicolini|first4=Doron|last4=Levy|date=May 3, 2016|journal=OncoImmunology|volume=5|issue=5|pages=e1122159|via=CrossRef|doi=10.1080/2162402X.2015.1122159|pmid=27467931|pmc=PMC4910749}}</ref> Considering the problem of drug resistance in cancer<ref>{{Cite journal|url=https://www.sciencedirect.com/science/article/pii/S1368764612000040|title=The dynamics of drug resistance: A mathematical perspective|first1=Orit|last1=Lavi|first2=Michael M.|last2=Gottesman|first3=Doron|last3=Levy|date=February 1, 2012|journal=Drug Resistance Updates|volume=15|issue=1|pages=90–97|via=ScienceDirect|doi=10.1016/j.drup.2012.01.003}}</ref> he suggested a simple compartmental system of ordinary differential equations to model it<ref>{{Cite web|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877932/|title=AN ELEMENTARY APPROACH TO MODELING DRUG RESISTANCE IN CANCER - PMC}}</ref> and stated that drug resistance depends on the turnover rate of cancer cells.<ref>{{Cite web|url=https://link.springer.com/chapter/10.1007/978-3-642-14998-6_141|title=Drug Resistance always Depends on the Turnover Rate|first1=C.|last1=Tomasetti|first2=D.|last2=Levy|editor-first1=Keith E.|editor-last1=Herold|editor-first2=Jafar|editor-last2=Vossoughi|editor-first3=William E.|editor-last3=Bentley|date=August 11, 2010|publisher=Springer|pages=552–555|via=Springer Link|doi=10.1007/978-3-642-14998-6_141}}</ref> Additionally, he extended a model of drug resistance in solid tumors to explore the dynamics of resistance levels and the emergence of heterogeneous tumors in response to chemotherapy.<ref>{{Cite journal|url=https://doi.org/10.1007/s11538-017-0359-1|title=Modeling the Dynamics of Heterogeneity of Solid Tumors in Response to Chemotherapy|first1=Heyrim|last1=Cho|first2=Doron|last2=Levy|date=December 1, 2017|journal=Bulletin of Mathematical Biology|volume=79|issue=12|pages=2986–3012|via=Springer Link|doi=10.1007/s11538-017-0359-1}}</ref><ref>{{Cite journal|url=https://doi.org/10.1007/s11538-017-0334-x|title=Modeling the Transfer of Drug Resistance in Solid Tumors|first1=Matthew|last1=Becker|first2=Doron|last2=Levy|date=October 1, 2017|journal=Bulletin of Mathematical Biology|volume=79|issue=10|pages=2394–2412|via=Springer Link|doi=10.1007/s11538-017-0334-x}}</ref> Conducting a study on cervical cancer, he investigated the efficacy of combination immunotherapy using engineered T cells and IL-2.<ref>{{Cite journal|url=https://www.sciencedirect.com/science/article/pii/S0022519320302587|title=Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer|first1=Heyrim|last1=Cho|first2=Zuping|last2=Wang|first3=Doron|last3=Levy|date=November 21, 2020|journal=Journal of Theoretical Biology|volume=505|pages=110403|via=ScienceDirect|doi=10.1016/j.jtbi.2020.110403}}</ref> Moreover, he assessed the influence of cell density,<ref>{{cite web|url=https://aacrjournals.org/cancerres/article/76/10/2882/609063/Mathematical-Modeling-Reveals-That-Changes-to|title=Mathematical Modeling Reveals That Changes to Local Cell Density Dynamically Modulate Baseline Variations in Cell Growth and Drug Response}}</ref> intratumoral heterogeneity,<ref>{{cite web|url=https://aacrjournals.org/cancerres/article/73/24/7168/586395/The-Role-of-Cell-Density-and-Intratumoral|title=The Role of Cell Density and Intratumoral Heterogeneity in Multidrug Resistance}}</ref> and mutations in multidrug resistance,<ref>{{Cite journal|url=https://doi.org/10.1007/s11538-014-9936-8|title=The Impact of Cell Density and Mutations in a Model of Multidrug Resistance in Solid Tumors|first1=James|last1=Greene|first2=Orit|last2=Lavi|first3=Michael M.|last3=Gottesman|first4=Doron|last4=Levy|date=March 1, 2014|journal=Bulletin of Mathematical Biology|volume=76|issue=3|pages=627–653|via=Springer Link|doi=10.1007/s11538-014-9936-8|pmid=24553772|pmc=PMC4794109}}</ref> considering the continuum model as the most suitable approach for modeling resistance heterogeneity in metastasis.<ref>{{Cite web|url=https://www.cell.com/trends/molecular-medicine/fulltext/S1471-4914(13)00225-6|title=Simplifying the complexity of resistance heterogeneity in metastasis: Trends in Molecular Medicine}}</ref><ref>{{Cite journal|url=https://www.sciencedirect.com/science/article/pii/S0307904X1830341X|title=Modeling continuous levels of resistance to multidrug therapy in cancer|first1=Heyrim|last1=Cho|first2=Doron|last2=Levy|date=December 1, 2018|journal=Applied Mathematical Modelling|volume=64|pages=733–751|via=ScienceDirect|doi=10.1016/j.apm.2018.07.025}}</ref> In collaboration with Heyrim Cho, he also investigated the impact of competition between cancer cells and healthy cells on optimal drug delivery and indicated that in scenarios with moderate competition, combination therapies are more effective, whereas in highly competitive situations, targeted drugs prove to be more effective.<ref>{{Cite journal|url=https://www.mmnp-journal.org/articles/mmnp/abs/2020/01/mmnp180193/mmnp180193.html|title=The impact of competition between cancer cells and healthy cells on optimal drug delivery|first1=Heyrim|last1=Cho|first2=Doron|last2=Levy|date=August 11, 2020|journal=Mathematical Modelling of Natural Phenomena|volume=15|pages=42|via=www.mmnp-journal.org|doi=10.1051/mmnp/2019043}}</ref>


==Awards and honors==
==Awards and honors==

Revision as of 05:22, 11 August 2023

Doron Levy
Occupation(s)Mathematician, scientist, magician, and academic
Academic background
EducationB.Sc. in Mathematics and Physics
M.Sc. in Applied Mathematics
Ph.D. in Applied Mathematics
Alma materTel Aviv University
ThesisTopics in Approximate Methods for Non-Linear Partial Differential Equations (1997)
Doctoral advisorEitan Tadmor
Academic work
InstitutionsÉcole normale supérieure (Paris)
Paris 6 University (Sorbonne University)
University of California, Berkeley
Lawrence Berkeley National Laboratory
Stanford University
University of Maryland, College Park

Doron Levy is a mathematician, scientist, magician, and academic. He is a Professor and Chair at the Department of Mathematics at the University of Maryland, College Park.[1] He is also the Director of the Brin Mathematics Research Center.[2]

Levy's research encompasses the field of numerical analysis, applied nonlinear PDEs, and biology and medical applications, particularly focusing on analyzing cancer dynamics, immunology, and cell motility. He has written more than 100 peer-reviewed articles. He is the recipient of the National Science Foundation Career Award.[3]

Levy is a Fellow of the John Simon Guggenheim Memorial Foundation[4] He is the Editor-in-Chief of ImmunoInformatics.[1]

Education

Levy earned his Baccalaureate degree in Mathematics and Physics in 1991 and completed a Masters in Applied Mathematics in 1994 from Tel Aviv University. His Master's thesis was titled "From Semi-Discrete to Fully-Discrete: The Stability of Runge-Kutta Schemes by the Energy Method".[5] In 1997, he received a Ph.D. in Applied Mathematics under the guidance of Eitan Tadmor, with a thesis on "Topics in Approximate Methods for Non-Linear Partial Differential Equations." Afterward, he held several post-doctorate fellowships at Laboratoire d'Analyse Numerique (University of Paris 6), École normale supérieure (Paris), University of California, Berkeley, and the Lawrence Berkeley National Laboratory.[1]

Career

Following his post-doctoral fellowship at Berkeley in 2000, Levy joined the Department of Mathematics at Stanford University as an Assistant Professor. In 2007, he was appointed as Associate Professor of Mathematics and a member of the Center for Scientific Computation and Mathematical Modeling (CSCAMM) at the University of Maryland, College Park. In 2014, he became a Pauli Fellow at the Wolfgang Pauli Institute of the University of Vienna in Austria.[6] Since 2011, he has been a Professor at the Department of Mathematics & Center for Scientific Computation and Mathematical Modeling of the University of Maryland, College Park.[7]

As of 2020, Levy has been a Chair at the Department of Mathematics & the Director of the Center for Scientific Computation and Mathematical Modeling (CSCAMM) of the University of Maryland, College Park.[1]

Research

Levy's research is focused on mathematical equations and biomedical applications of mathematics with a particular interest in cancer dynamics, drug resistance, drug delivery, immunology, imaging, and cell motility.[8]

Numerical analysis

During his early research career, Levy worked on developing and analyzing high-order numerical methods for approximating solutions to hyperbolic conservation law and related equations. He developed novel methods for approximating solutions to nonlinear partial differential equations including Euler equations, Navier-Stokes equations, Hamilton-Jacobi equations, nonlinear dispersive equations. Some of the approximation methods he developed used Weighted Essentially Non-Oscillatory (WENO) schemes.[9] He developed a third-order central scheme for approximating solutions of multidimensional hyperbolic conservation laws[10] and 2D conservation laws using compact central WENO reconstructions.[11] In a series of works with Steve Bryson, he proposed new high-order central schemes[12] for approximating solutions of multidimensional Hamilton-Jacobi equations.[13][14]

Cancer dynamics and the immune system

Levy contributed to cancer dynamics by formulating a set of computational and mathematical tools designed for specific types of cancer.[15] He discussed the need for mathematical models to understand the complexity of breast and ovarian cancers[16] and proposed a model to explain the failure of transvaginal ultrasound-based screening in detecting low-volume high-grade serous ovarian cancer.[17] In a collaborative study, he investigated the effects of regulatory T cell switching the immune response and identified a biologically testable range for the switching parameter.[18] Furthermore, he presented mathematical models for studying cancer cell growth dynamics[19] in response to antimitotic drug treatment in vitro,[20] to understand the immunogenic effects of LSD1 inhibition on tumor growth and T cell dynamics,[21] and for the interaction between immune response and cancer cells in chronic myelogenous leukemia and analyzes the stability of steady states.[22]

Levy analyzed cancer's immune response mechanisms, particularly in chronic myeloid leukemia, providing insights into the role of the immune response and drug therapy in controlling the disease.[23] He also demonstrated that the autologous immune system may play a role in the BCR-ABL transcript variations observed in chronic phase chronic myelogenous leukemia patients on imatinib therapy.[24] Considering the problem of drug resistance in cancer[25] he suggested a simple compartmental system of ordinary differential equations to model it[26] and stated that drug resistance depends on the turnover rate of cancer cells.[27] Additionally, he extended a model of drug resistance in solid tumors to explore the dynamics of resistance levels and the emergence of heterogeneous tumors in response to chemotherapy.[28][29] Conducting a study on cervical cancer, he investigated the efficacy of combination immunotherapy using engineered T cells and IL-2.[30] Moreover, he assessed the influence of cell density,[31] intratumoral heterogeneity,[32] and mutations in multidrug resistance,[33] considering the continuum model as the most suitable approach for modeling resistance heterogeneity in metastasis.[34][35] In collaboration with Heyrim Cho, he also investigated the impact of competition between cancer cells and healthy cells on optimal drug delivery and indicated that in scenarios with moderate competition, combination therapies are more effective, whereas in highly competitive situations, targeted drugs prove to be more effective.[36]

Awards and honors

Selected articles

  • Levy, D., & Tadmor, E. (1998). From semidiscrete to fully discrete: Stability of Runge--Kutta schemes by the energy method. SIAM review, 40(1), 40-73.
  • Kim, P. S., Lee, P. P., & Levy, D. (2008). Dynamics and potential impact of the immune response to chronic myelogenous leukemia. PLoS computational biology, 4(6), e1000095.
  • Tomasetti, C., & Levy, D. (2010). Role of symmetric and asymmetric division of stem cells in developing drug resistance. Proceedings of the National Academy of Sciences, 107(39), 16766-16771.
  • Lavi, O., Greene, J. M., Levy, D., & Gottesman, M. M. (2013). The role of cell density and intratumoral heterogeneity in multidrug resistance. Cancer research, 73(24), 7168-7175.
  • Cho, H., & Levy, D. (2018). Modeling the chemotherapy-induced selection of drug-resistant traits during tumor growth. Journal of theoretical biology, 436, 120-134.

References

  1. ^ a b c d "Dr. Doron Levy, PhD - Editorial Board - ImmunoInformatics - Journal - Elsevier". www.journals.elsevier.com.
  2. ^ "MRC Director". Brin MRC.
  3. ^ a b "NSF Award Search: Award # 0820817 - CAREER: Partial Differential Equation-based Image Processing with Applications to Radiation Oncology". www.nsf.gov.
  4. ^ a b "Doron Levy". John Simon Guggenheim Memorial Foundation...
  5. ^ Levy, Doron; Tadmor, Eitan (January 11, 1998). "From Semidiscrete to Fully Discrete: Stability of Runge--Kutta Schemes by The Energy Method". SIAM Review. 40 (1): 40–73. doi:10.1137/S0036144597316255 – via CrossRef.
  6. ^ "Wolfgang Pauli Institute (WPI)". www.wpi.ac.at.
  7. ^ "Department of Mathematics - Levy, Doron". www-math.umd.edu.
  8. ^ Cite error: The named reference bbb was invoked but never defined (see the help page).
  9. ^ Levy, Doron; Puppo, Gabriella; Russo, Giovanni (May 1, 2000). "On the behavior of the total variation in CWENO methods for conservation laws". Applied Numerical Mathematics. 33 (1): 407–414. doi:10.1016/S0168-9274(99)00107-5 – via ScienceDirect.
  10. ^ Levy, Doron; Puppo, Gabriella; Russo, Giovanni (January 11, 2000). "Compact Central WENO Schemes for Multidimensional Conservation Laws". SIAM Journal on Scientific Computing. 22 (2): 656–672. doi:10.1137/S1064827599359461 – via CrossRef.
  11. ^ Levy, Doron; Puppo, Gabriella; Russo, Giovanni (May 1, 2000). "A third order central WENO scheme for 2D conservation laws". Applied Numerical Mathematics. 33 (1): 415–421. doi:10.1016/S0168-9274(99)00108-7 – via ScienceDirect.
  12. ^ Bryson, S.; Levy, D. (August 11, 2003). Brezzi, Franco; Buffa, Annalisa; Corsaro, Stefania; Murli, Almerico (eds.). "High-order central WENO schemes for 1D Hamilton-Jacobi equations". Springer Milan. pp. 45–54. doi:10.1007/978-88-470-2089-4_4 – via Springer Link.
  13. ^ Bryson, Steve; Levy, Doron (January 11, 2003). "High-Order Central WENO Schemes for Multidimensional Hamilton-Jacobi Equations". SIAM Journal on Numerical Analysis. 41 (4): 1339–1369. doi:10.1137/S0036142902408404 – via CrossRef.
  14. ^ Levy, Doron; Nayak, Suhas; Shu, Chi‐Wang; Zhang, Yong‐Tao (January 11, 2006). "Central WENO Schemes for Hamilton–Jacobi Equations on Triangular Meshes". SIAM Journal on Scientific Computing. 28 (6): 2229–2247. doi:10.1137/040612002 – via CrossRef.
  15. ^ Peet, M. M.; Kim, P. S.; Niculescu, S.-I.; Levy, D. (January 11, 2009). "New Computational Tools for Modeling Chronic Myelogenous Leukemia". Mathematical Modelling of Natural Phenomena. 4 (2): 119–139. doi:10.1051/mmnp/20094206 – via Cambridge University Press.
  16. ^ Botesteanu, Dana‐Adriana; Lipkowitz, Stanley; Lee, Jung‐Min; Levy, Doron (July 11, 2016). "Mathematical models of breast and ovarian cancers". WIREs Systems Biology and Medicine. 8 (4): 337–362. doi:10.1002/wsbm.1343. PMC 4911289. PMID 27259061 – via CrossRef.{{cite journal}}: CS1 maint: PMC format (link)
  17. ^ Botesteanu, Dana-Adriana; Lee, Jung-Min; Levy, Doron (June 3, 2016). "Modeling the Dynamics of High-Grade Serous Ovarian Cancer Progression for Transvaginal Ultrasound-Based Screening and Early Detection". PLOS ONE. 11 (6): e0156661. doi:10.1371/journal.pone.0156661. PMC 4892570. PMID 27257824 – via PLoS Journals.{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link)
  18. ^ Wilson, Shelby; Levy, Doron (October 1, 2013). "Functional Switching and Stability of Regulatory T Cells". Bulletin of Mathematical Biology. 75 (10): 1891–1911. doi:10.1007/s11538-013-9875-9 – via Springer Link.
  19. ^ Greene, James M.; Levy, Doron; Fung, King Leung; Souza, Paloma S.; Gottesman, Michael M.; Lavi, Orit (February 21, 2015). "Modeling intrinsic heterogeneity and growth of cancer cells". Journal of Theoretical Biology. 367: 262–277. doi:10.1016/j.jtbi.2014.11.017 – via ScienceDirect.
  20. ^ Lorz, Alexander; Botesteanu, Dana-Adriana; Levy, Doron (August 11, 2017). "Modeling Cancer Cell Growth Dynamics In vitro in Response to Antimitotic Drug Treatment". Frontiers in Oncology. 7. doi:10.3389/fonc.2017.00189/full?&utm_source=email_to_authors_&utm_medium=email&utm_content=t1_11.5e1_author&utm_campaign=email_publication&field=&journalname=frontiers_in_oncology&id=276810 – via Frontiers.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  21. ^ Milzman, Jesse; Sheng, Wanqiang; Levy, Doron (January 12, 2021). "Modeling LSD1-Mediated Tumor Stagnation". Bulletin of Mathematical Biology. 83 (2): 15. doi:10.1007/s11538-020-00842-8 – via Springer Link.
  22. ^ Besse, Apollos; Clapp, Geoffrey D.; Bernard, Samuel; Nicolini, Franck E.; Levy, Doron; Lepoutre, Thomas (May 1, 2018). "Stability Analysis of a Model of Interaction Between the Immune System and Cancer Cells in Chronic Myelogenous Leukemia". Bulletin of Mathematical Biology. 80 (5): 1084–1110. doi:10.1007/s11538-017-0272-7 – via Springer Link.
  23. ^ "The role of the autologous immune response in chronic myelogenous leukemia".
  24. ^ Clapp, Geoffrey D.; Lepoutre, Thomas; Nicolini, Franck E.; Levy, Doron (May 3, 2016). "BCR-ABL transcript variations in chronic phase chronic myelogenous leukemia patients on imatinib first-line: Possible role of the autologous immune system". OncoImmunology. 5 (5): e1122159. doi:10.1080/2162402X.2015.1122159. PMC 4910749. PMID 27467931 – via CrossRef.{{cite journal}}: CS1 maint: PMC format (link)
  25. ^ Lavi, Orit; Gottesman, Michael M.; Levy, Doron (February 1, 2012). "The dynamics of drug resistance: A mathematical perspective". Drug Resistance Updates. 15 (1): 90–97. doi:10.1016/j.drup.2012.01.003 – via ScienceDirect.
  26. ^ "AN ELEMENTARY APPROACH TO MODELING DRUG RESISTANCE IN CANCER - PMC".
  27. ^ Tomasetti, C.; Levy, D. (August 11, 2010). Herold, Keith E.; Vossoughi, Jafar; Bentley, William E. (eds.). "Drug Resistance always Depends on the Turnover Rate". Springer. pp. 552–555. doi:10.1007/978-3-642-14998-6_141 – via Springer Link.
  28. ^ Cho, Heyrim; Levy, Doron (December 1, 2017). "Modeling the Dynamics of Heterogeneity of Solid Tumors in Response to Chemotherapy". Bulletin of Mathematical Biology. 79 (12): 2986–3012. doi:10.1007/s11538-017-0359-1 – via Springer Link.
  29. ^ Becker, Matthew; Levy, Doron (October 1, 2017). "Modeling the Transfer of Drug Resistance in Solid Tumors". Bulletin of Mathematical Biology. 79 (10): 2394–2412. doi:10.1007/s11538-017-0334-x – via Springer Link.
  30. ^ Cho, Heyrim; Wang, Zuping; Levy, Doron (November 21, 2020). "Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer". Journal of Theoretical Biology. 505: 110403. doi:10.1016/j.jtbi.2020.110403 – via ScienceDirect.
  31. ^ "Mathematical Modeling Reveals That Changes to Local Cell Density Dynamically Modulate Baseline Variations in Cell Growth and Drug Response".
  32. ^ "The Role of Cell Density and Intratumoral Heterogeneity in Multidrug Resistance".
  33. ^ Greene, James; Lavi, Orit; Gottesman, Michael M.; Levy, Doron (March 1, 2014). "The Impact of Cell Density and Mutations in a Model of Multidrug Resistance in Solid Tumors". Bulletin of Mathematical Biology. 76 (3): 627–653. doi:10.1007/s11538-014-9936-8. PMC 4794109. PMID 24553772 – via Springer Link.{{cite journal}}: CS1 maint: PMC format (link)
  34. ^ "Simplifying the complexity of resistance heterogeneity in metastasis: Trends in Molecular Medicine".
  35. ^ Cho, Heyrim; Levy, Doron (December 1, 2018). "Modeling continuous levels of resistance to multidrug therapy in cancer". Applied Mathematical Modelling. 64: 733–751. doi:10.1016/j.apm.2018.07.025 – via ScienceDirect.
  36. ^ Cho, Heyrim; Levy, Doron (August 11, 2020). "The impact of competition between cancer cells and healthy cells on optimal drug delivery". Mathematical Modelling of Natural Phenomena. 15: 42. doi:10.1051/mmnp/2019043 – via www.mmnp-journal.org.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Doron_Levy&oldid=1169772956"